|
Volumn 39, Issue 11, 2004, Pages 1734-1738
|
Legionnaires disease and the updated IDSA guidelines for community-acquired pneumonia [4] (multiple letters)
|
Author keywords
[No Author keywords available]
|
Indexed keywords
AZITHROMYCIN;
BETA LACTAM ANTIBIOTIC;
CEPHALOSPORIN DERIVATIVE;
CLARITHROMYCIN;
DIRITHROMYCIN;
ERYTHROMYCIN;
GREPAFLOXACIN;
LEVOFLOXACIN;
MACROLIDE;
OFLOXACIN;
PENICILLIN DERIVATIVE;
RIFAMPICIN;
ROXITHROMYCIN;
SPARFLOXACIN;
ANTIBIOTIC RESISTANCE;
ANTIBIOTIC THERAPY;
BACTERIUM ISOLATION;
CLINICAL TRIAL;
COMMUNITY ACQUIRED PNEUMONIA;
COST BENEFIT ANALYSIS;
DIAGNOSTIC ACCURACY;
DIAGNOSTIC TEST;
DIFFERENTIAL DIAGNOSIS;
DRUG COST;
DRUG INDICATION;
EPIDEMIC;
HOSPITAL ADMISSION;
HOSPITALIZATION;
HUMAN;
IMMUNOCOMPETENCE;
INCIDENCE;
LABORATORY TEST;
LEGIONELLA;
LEGIONNAIRE DISEASE;
LETTER;
LOBAR PNEUMONIA;
MEDICAL SOCIETY;
MORBIDITY;
MORTALITY;
PENICILLIN RESISTANCE;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
RISK FACTOR;
SCORING SYSTEM;
SCREENING;
SERODIAGNOSIS;
SIDE EFFECT;
TREATMENT OUTCOME;
COMMUNITY-ACQUIRED INFECTIONS;
HUMANS;
LEGIONNAIRES' DISEASE;
PNEUMONIA, BACTERIAL;
PRACTICE GUIDELINES;
|
EID: 9644272636
PISSN: 10584838
EISSN: None
Source Type: Journal
DOI: 10.1086/425921 Document Type: Letter |
Times cited : (13)
|
References (0)
|